Nanoporous carbon adsorbent to modify liver disease
EASL LiverTree™, Rajiv Jalan, 218980
The Regenerating Liver is Vulnerable to Lymph circulating Intestinal Bacteria
EASL LiverTree™, Manuel Jakob, 218979
Fecal transplantation in cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 218977
Next generation probiotics
EASL LiverTree™, Philippe Langella, 218976
Depletion of Paneth cells is associated with decreased portal hypertension and angiogenesis after partial portal vein ligation in mice.
EASL LiverTree™, Mohsin Hassan, 217858
Gut Permeability in Biliary Atresia Post-Kasai Portoenterostomy
EASL LiverTree™, Vandana Jain, 218935
Impact of alive probiotics supplementation with absorbent smectite gel in NAFLD management: evidence from animals to randomized clinical studies
EASL LiverTree™, Nazarii Kobyliak, 217859
Microbiota modulation by synbiotic modify gut flora and reduces obesity without improvement of fatty liver in OB OB mice
EASL LiverTree™, Claudia Oliveira, 218934
The impact of ileal pouch anal anastomosis on post liver transplant outcomes in primary sclerosing cholangitis
EASL LiverTree™, Palak Trivedi, 217862
Gut microbiota and host immunity interaction in health and disease
EASL LiverTree™, Harry Sokol, 218973
Industry point of view: BiomX, Targeting Chronic Microbiome Diseases by Phages
EASL LiverTree™, Eyal Weinstock, 218972
Industry point of view: Targeting the duodenum for metabolic gain
EASL LiverTree™, David Maggs, 218971
Industry point of view: Synthetic biotic medicines in liver disease
EASL LiverTree™, Caroline Kurtz, 218970
Assessment of intestinal permeability and translocation. Endoscopy and imaging tools
EASL LiverTree™, Reiner Wiest, 218969
Gnotobiotic animal models
EASL LiverTree™, Siegfried Hapfelmeier, 218968
Small intestinal bacterial overgrowth is associated with arterial hypotension in cirrhosis
EASL LiverTree™, Roman Maslennikov, 217844
Characterization of gut microbiome in Asian Indian nonalcoholic steatohepatitis subjects vis-`a-vis healthy controls
EASL LiverTree™, Manvi Vernekar, 217855
Bacterial translocation during experimental cirrhosis coincides with the infiltration of inflammatory monocytes in the gut
EASL LiverTree™, Lore Meelberghs, 217854
Increased prevalence of low frequency and rare NOD2 variants in patients with cirrhosis
EASL LiverTree™, Matthias Reichert, 217857
Elafin reduces intestinal inflammation and modifies the type, but not the rate, of bacterial translocation: Preliminary results
EASL LiverTree™, María Ubeda, 217856
Linking Endoplasmic Reticulum Stress to intestinal barrier in Inflammatory Bowel Disease. 
EASL LiverTree™, Beatriz Martin, 217842
Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes
EASL LiverTree™, Ilaria Barchetta, 217850
Obesity- related macrophage activation and inflammation but not bacterial translocation are associated with biopsy- proven NAFLD in HIV Mono-Infection
EASL LiverTree™, James Maurice, 217851
The Potential Involvement of the Gut-Liver Axis in Mature-Onset Obesity and Fatty Liver Disease Induced by IL-6 Tran-Signaling Blockade
EASL LiverTree™, Jonathan H. Axelrod, 218932
THE MODIFICATION OF MICROBIAL TRANSLOCATION IN HCV PATIENTS UNDERGOING DIRECTLY ACTING ANTIVIRAL TREATMENT
EASL LiverTree™, Barbara Lattanzi, 217841
Intestinal inflammation driven by dysbiosis promotes the barrier dysruption and gut bacterial translocation in rats with cirrhosis
EASL LiverTree™, Leticia Munoz, 217853
Elevated expressions of Sodium taurocholate co-transporting polypeptide (NTCP) on NK cells impaired their function and contribute to liver fibrosis
EASL LiverTree™, Johnny Amer, 217852
Intestinal barrier failure in cirrhosis: impact on complications
EASL LiverTree™, Agustin Albillos, 218964
Interaction between intestine and liver in alcoholic liver disease
EASL LiverTree™, Jasmohan S Bajaj, 218963
The gut microbiota in NAFLD and associated metabolic disorders
EASL LiverTree™, Nathalie Delzenne, 218962
Effect of Ginkgolide A on regulating PXR and tight junction proteins in experimental cirrhosis
EASL LiverTree™, Balasubramaniyan Vairappan, 217840
Intestinal permeability and inflammation are associated with hepatocellular carcinoma in patients with NAFLD-related liver cirrhosis
EASL LiverTree™, Francesca Romana Ponziani, 217848
Severity of obesity-associated NAFLD inversely correlates with Akkermansia spp. abundance in germ-free mice transplanted with intestinal microbiota from high fat diet and quercetin treated donors.
EASL LiverTree™, David Porras-Sanabria, 217846
Age and gender disparity in binge drinking: a gut-liver axis story
EASL LiverTree™, Arantza Lamas Paz, 217839
Inhibition of hepatic bile acid uptake prolongs bile acid signalling, leading to reduced adiposity and increased GLP-1 secretion
EASL LiverTree™, Joanne Donkers, 218960
Intestinal mucus and gut-vascular barrier in liver cirrhosis: Entry sites for bacterial translocation from the gut to the liver independent from portal hypertension and lymphatic route
EASL LiverTree™, Marcel Sorribas, 218959
Industry point of view: Ammonia and metabolite uptake of VS-01
EASL LiverTree™, Vincent Forster, 218958
Antibiotics to Modulate the Gut Liver Axis and RifSys RCT Preliminary Metagenomics Data
EASL LiverTree™, Vishal Patel, 218957
Bile acid signaling and the FXR pathway
EASL LiverTree™, Michael Trauner, 218954
Liver and gut-derived inflammation in the pathophysiology of ACLF
EASL LiverTree™, Jonel Trebicka, 218950
The gut-liver axis in the control of hepatobiliary malignancies
EASL LiverTree™, Gianluca Svegliati-Baroni, 218949
Contribution of intestinal inflammation and dysbiosis to cholestatic liver disease
EASL LiverTree™, Johannes R. Hov, 218948
Disturbances of gut microbiota on liver inflammation and fibrosis
EASL LiverTree™, Bernd Schnabl, 218947
miR-21 contributes to the onset and progression of liver disease through the deregulation of small intestine permeability
EASL LiverTree™, André Santos, 217836
HCC Progression in NASH: Effects of bile acid signalling and microbiota
EASL LiverTree™, Svenja Sydor, 217835
MAdCAM-1/alpha4 beta7 integrin-mediated lymphocyte endothelium interactions exacerbate acute immune-mediated hepatitis in mice
EASL LiverTree™, Angela Schippers, 218930
ORAL GLUTAMINE CHALLENGE IS REGULATED BY GENES IMPLICATED ON AMMONIA METABOLISM
EASL LiverTree™, Antonio Gil-Gomez, 217834
Genetic factors of hepatic encephalopathy on patients with cirrhosis: candidate gene study
EASL LiverTree™, Antonio Gil-Gomez, 217837
Sodium taurocholate co-transporting polypeptide (NTCP) as a novel checkpoint in NK cells activity in liver fibrosis
EASL LiverTree™, Ahmad Salhab, 217833
Bile acid signaling in the gut-liver axis
EASL LiverTree™, Oihane Garcia-Irigoyen, 218944
Circulation and homing of immune cells
EASL LiverTree™, David Adams, 218943
Structure and function of the intestinal barrier
EASL LiverTree™, Maria Rescigno, 218942
Opening and state-of-the-art: Chair
EASL LiverTree™, Prof. Agustín Albillos, Dr Maria Rescigno and Dr. Andrea De Gottardi, 221454
From the Editor’s desk...
EASL LiverTree™, Richard Moreau, 226782
Ammonia: This is not the end but rather the end of the beginning
EASL LiverTree™, Christopher F. Rose, 226784
A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses
EASL LiverTree™, Jan Felix Drexler, 226785
Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study
EASL LiverTree™, Pan Zhao, 226786
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
EASL LiverTree™, George Papatheodoridis, 226787
Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release
EASL LiverTree™, Peter Nissen Bjerring, 226788
Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma
EASL LiverTree™, Woo Kyoung Jeong, 226789
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma
EASL LiverTree™, Gi-Won Song, 226790
Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial
EASL LiverTree™, Boris Guiu, 226791
No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm
EASL LiverTree™, Jean-Yves Mabrut, 226792
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
EASL LiverTree™, Didier Samuel, 226793
O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis
EASL LiverTree™, Yuanyuan Ruan, 226794
AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation
EASL LiverTree™, Helene GILGENKRANTZ, 226795
Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma
EASL LiverTree™, Wei-Ping Zhou, 226796
Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma
EASL LiverTree™, Gregory Gores, 226797
High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance
EASL LiverTree™, Shira ZELBER-SAGI, 226798
Prolactin improves hepatic steatosis via CD36 pathway
EASL LiverTree™, Yan Bi, 226799
Mesenchymal stromal cell therapy for liver diseases
EASL LiverTree™, Soon Koo Baik, 226801
Paediatric fatty liver disease (PeFLD): All is not NAFLD – Pathophysiological insights and approach to management
EASL LiverTree™, Anil Dhawan, 226802
Quality measurement and improvement in liver transplantation
EASL LiverTree™, Amit K. Mathur, 226803
Patient prioritisation in HCC treatment: All (good) things come in threes
EASL LiverTree™, Peter Galle, 226804
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure
EASL LiverTree™, Adel Abdel-Moneim, 226805
Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns
EASL LiverTree™, Qiang Xia, 226806
Reply to: “Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns”
EASL LiverTree™, Feng SHEN, 226807
Association of hepatitis E virus infection and myasthenia gravis: A pilot study
EASL LiverTree™, Ling Wang, 226808
Reply to: “Association of hepatitis E virus infection and myasthenia gravis: A pilot study”
EASL LiverTree™, Harry Dalton, 226809
Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach
EASL LiverTree™, Pierre Deltenre, 226810
Reply to: “Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach”
EASL LiverTree™, Jules Dienstag, 226811
Has the time come for using MELD-Sarcopenia score?
EASL LiverTree™, Virendra Singh, 226812
May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
EASL LiverTree™, Manuela Merli, 226813
Reply to: “May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?” and “Has the time come for using MELD-Sarcopenia score?”
EASL LiverTree™, Jeroen van Vugt, 226814
Redefining futility in DCD liver transplantation in the era of novel perfusion technologies
EASL LiverTree™, Gabriel C. Oniscu, 226815
Reply to: “Redefining futility in DCD liver transplantation in the era of novel perfusion technologies”
EASL LiverTree™, Paolo Muiesan, 226816
The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode
EASL LiverTree™, Thomas Damgaard Sandahl, 226817
Reply to: “The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode”
EASL LiverTree™, Ewan H Forrest, 226818
Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe?
EASL LiverTree™, Sushun Liu, 226819
Reply to: “Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe?”
EASL LiverTree™, Patrick Starlinger, 226820
Corrigendum to “Targeting the gut-liver axis in liver disease” [J Hepatol 67 (2017) 1084–1103]
EASL LiverTree™, Reiner Wiest, 226821
Corrigendum to “Pharmacotherapy for NASH: Current and emerging” [J Hepatol 68 (2017) 362–375]
EASL LiverTree™, Stephen Harrison, 226822
EASL Recognition Award Recipient 2018: Prof. Didier Samuel
EASL LiverTree™, Daniel Shouval, 218587
EASL Recognition Award Recipient 2018: Prof. Mario Mondelli
EASL LiverTree™, Michael P. Manns, 218588
Effects of the gut–liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver
EASL LiverTree™, Lorenzo Annibale Orci, 218603
Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation
EASL LiverTree™, Jörn Schattenberg, 218604
Reply to: “The role of NAFLD in extrahepatic malignancies: The importance of ruling out the effect of obesity”
EASL LiverTree™, Han Chu Lee, 218619
Association between beverage consumption and liver fibrosis
EASL LiverTree™, Yisheng Huang, 218620

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings